| Document Date: 2013-12-02 15:45:02
Open Document File Size: 1,63 MBShare Result on Facebook
City Dublin / Siena / / Company 2Astex Pharmaceuticals Inc. / Astex Pharmaceuticals / / Country Italy / / Event FDA Phase / / Facility University Hospital of Siena / / IndustryTerm cancer therapeutics / diluent solution / / MedicalCondition human melanoma / Tumor / poorly immunogenic murine mammary carcinoma TS/A / ovarian cancer / palpable tumor / murine mammary carcinoma / cancer / tumors / tumor volumes / myelodysplastic syndromes / mammary carcinoma TS/A / hepatocellular carcinoma / acute myeloid leukemia / mouse cancer H2O P1A / cancer testis antigens / / MedicalTreatment cancer therapeutics / / Organization Department of Oncology / University Hospital of Siena / / Person Alessia / / / Position syngenic mouse model / / Product carboplatin / SQ injection / bp 100 / SGI-110 / SGI / / PublishedMedium 8 Days / / URL www.astx.com” / /
SocialTag |
abstract # A256 Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model Alessia